WO1992009277A1 - Nutrient supply - Google Patents

Nutrient supply Download PDF

Info

Publication number
WO1992009277A1
WO1992009277A1 PCT/SE1991/000810 SE9100810W WO9209277A1 WO 1992009277 A1 WO1992009277 A1 WO 1992009277A1 SE 9100810 W SE9100810 W SE 9100810W WO 9209277 A1 WO9209277 A1 WO 9209277A1
Authority
WO
WIPO (PCT)
Prior art keywords
glutamine
solution
composition according
composition
freeze
Prior art date
Application number
PCT/SE1991/000810
Other languages
French (fr)
Inventor
Reinhold Kihlberg
Björn NORRLIND
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of WO1992009277A1 publication Critical patent/WO1992009277A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides

Definitions

  • the present invention relates to a preparation which makes possible the parenteral or oral administration of a balanced nutrient solution containing a high concen ⁇ tration of glutamine and gluta ine derivative or gluta- mine precursors.
  • the invention relates to a preparation which contains L-glutamine and also at least one glutamine derivative, preferably glycyl-L-glutamine and/or L-alanyl-L-glutamine or a precursor of L-glutamine, preferably alpha-keto-glutaric acid and salts/derivatives thereof.
  • glutamine derivative preferably glycyl-L-glutamine and/or L-alanyl-L-glutamine or a precursor of L-glutamine, preferably alpha-keto-glutaric acid and salts/derivatives thereof.
  • N-acetyl-L-gluta ⁇ mine can also be used.
  • the invention also relates to a nutrient solution and to a method of preparing the same, said solution optionally containing such nutrients as amino acids, fats, particu ⁇ larly emulsified fats, energy substrates, such as glu ⁇ cose, sugar alcohols and keto-a ⁇ ids, electrolytes, vitamins and trace elements.
  • nutrients such as amino acids, fats, particu ⁇ larly emulsified fats, energy substrates, such as glu ⁇ cose, sugar alcohols and keto-a ⁇ ids, electrolytes, vitamins and trace elements.
  • Intravenous nutrient therapy has become progressively more complete and better balanced as the significance of new substances, or the significance of substances which have earlier been overlooked, has become more apparent.
  • gluta ⁇ mine is highly significant when used as a component of nutrient support compositions.
  • glutamine is the most significant transporter by means of which nitrogen is transported from muscle to intestines and liver.
  • glutamine has a stimulating effect on the synthesis of proteins in muscle tissue.
  • the store of free glutamine in skeletal muscle diminishes drasti- cally in patients who have suffered serious trauma, surgical operations, sepsis, etc. (Vinnars E. , Berg- str ⁇ m, and First, P.
  • Glutamine also constitutes an essential energy source for the intestinal mucus membrane (Windmueller, H.G., Spaeth, A.E.: Identification of Ketone Bodies and Glutamine as the Major Respiratory Fuels in Vivo for Postabsorptive Rat Small Intestine, J. Biol. Chem. 253:69-76 (1978).
  • Total intravenous nutrition results in some degree of atrophication or wasting of the intes ⁇ tine mucus membrane. Animal experimentation has shown that glutamine is able to counteract this negative effect, when administered intravenously.
  • the administration of glutamine to animals suffering from experimentally induced bowel damage has been found to result in a lower mortality rate (Hwang, T.L. , et al: Preservation of Small Bowel Mucosa Using Glutamine-Enriched Parenteral Nutrition. Surg. Forum 37:56-58 (1986).
  • a nutrient solution which contains glutamine together with other nutritious substances is highly desirable.
  • solu ⁇ tions which contain glutamine cannot be sterilized by autoclaving, since free glutamine in solution is not heat resistant.
  • a solution which contains gluta ⁇ mine is heated or stored for long periods of time at room temperature, the glutamine will decompose to ammo ⁇ nia and pyroglutamic acid.
  • Such substances are unac ⁇ ceptable in nutrient solutions intended for intravenous administration. Consequently, present-day commercially available parenteral nutrient amino acid solutions con ⁇ tain no glutamine.
  • Alpha-keto-glutarate (AKG) is active in various trans- amination reactions and thereby adopts a central roll in the amino acid metabolism. It has long been known that glutamine can be formed from AKG via glutamic acid. It has also been found that when administered intra ⁇ venously, AKG is able to counteract the depletion of the free content of glutamine intracellular in muscle after operative trauma (Wernerman, et al, The Lancet 335, No. 8691, 701-703, 1990). This indicates that AKG could be used as a glutamine precursor in an intravenous nutrient supply or support. Wilmore (WO 87/01587) discloses the use of glutamine in quantities of up to 0.2-3 g/kg of body weight and day in conjunction with trauma.
  • Veech (WO 87/03806) utilizes glutamine, optionally in mixture with AKG in small quantities, to influence the redox system.
  • Vinnars discloses the composition of a posttraumatic solution treatment. Although based on a conventional amino acid mixture, this composition is characterized in that it also includes 5-30 g glutamine and/or 5-25 g AKG per litre, and optional L-asparagine and acetoacetate.
  • peptide-bound glutamine e.g. glycyl-L-glutamine and also L-alanyl-L-glutamine are acceptably stable when subjected to heat treatment in solution; it has also been found that these substances are biologically active as a glutamine source. This also applies to N-acetyl-L-glutamine.
  • F ⁇ rst, et al discloses an amino acid solution which is characterized in that it contains glutamine in the form of water-soluble dipeptides or tripeptides.
  • Adibi (BE-887941) discloses an aqueous solution which contains at least two dipeptides or tripeptides having a single glycine molecule as the N-terminal amino acid.
  • Nutrient solutions for parenteral administration are normally sterilized at about 121°C for 15 minutes, in accordance with standardized techniques.
  • the solutions contain components that are able to react with one another or which become unstable when subjected to heat, it is not, however, possible to follow the standardized procedures.
  • none of the commercially available amino acid solutions contains glutamine.
  • SE 8902544-9 discloses a method of solving the problem of the instability of glutamine, this solution involving the sterilization of powdered glutamine by ionizing radiation prior to mixing the glutamine with the remaining components in the nutrient solution.
  • a third possibility is to supply the glutamine in the form of a precursor which can be converted at least partially to glutamine in the body.
  • a fourth possibility is one of administering glutamine in the form of a derivative, preferably in the form of a dipeptide.
  • the other amino acid in the dipeptide preferably glycine or alanine
  • a daily dosage of 60 g glutamine corresponds, e.g., to 37 grams of alanine, alternatively 31 grams of glycine, depending on whether the supply is effected in the form of the alanyl-peptide or the glycyl-peptide). From the physiological aspect, this implies unfavourable quantities of glycine or alanine.
  • the peptide-bound ala ⁇ nine or the peptide-bound glycine is also added to corresponding free amino acid in the solution, and the patient is thereby liable to obtain a negative imbalance in the amino acid conversion.
  • a supply of 80-90 g of a dipeptide would be likely to exceed the ability of the organism to cleave (hydrolyze) the peptide in order to release l-glutamine. This would result in a drastic increase in plasma levels of the peptide, pronounced secretion of the unconsumed peptide in the urine and therewith poor use of the peptide administered.
  • the dipeptides in question are, in many cases, not completely stable during the sterilizing process or when stored for long periods of time at room temperature. Consequently, the dipeptide solution must be subjected to comprehensive analytical and biological processes in order to ensure the quality of the peptide solutions from a technical and toxicolog- ical aspect.
  • the price per unit of glutamine based on a glutamine peptide is about 10-20 times higher than the price of a corresponding quantity of pure L-glutamine.
  • the proposed invention enables large quantities of glutamine to be administered without interference from the aforediscussed problems concerning technical insta- bility, large volumes when dissolving and administering glutamine, and, particularly with respect to peptide supply, high costs, metabolic imbalances and physiologi ⁇ cal overloads.
  • the invention relates to a preparation for oral or parenteral use, characterized in that the preparation includes free L-glutamine and also at least one L- glutamine derivative and optionally at least one L- glutamine precursor, said preparation being prepared aseptically and freeze-dried; in that the preparation is in powder form and is radiation sterilized, or is in the form of a solution which is stored at low temperature, preferably in a frozen state.
  • low temperature is meant a temperature lower than room temperature, and preferably a temperature within the range of 2-8 ⁇ C.
  • the derivative preferably consists of peptides, such as glycyl-L-glutamine and/or L-alanyl-L-glutamine, and the precursor may consist of alpha-keto-glutaric acid or the salt/derivative thereof.
  • the derivative may also con ⁇ sist of N-acetyl-L-glutamine.
  • the preparation may also contain other nutrient components, alternatively technical auxiliary sub ⁇ stances, such as carbohydrates, sugar alcohols, vitamins and/or amino acids, preferably in freeze-dried form.
  • the present invention also relates to a nutrient solu ⁇ tion which contains the aforedescribed preparation and further amino acids, fat emulsion, energy substrate, such as glucose, sugar alcohols and keto-acids, vita- mins, electrolytes and/or trace elements.
  • the claimed preparation is produced by dissolving the preparation components, sterile filtering the solution and thereafter freeze- drying the sterile solution.
  • the components are mixed together in powder form and the resultant mixture is then sterilized by radiation.
  • the preparation compo ⁇ nents are mixed in solution and the solution is sterile filtered and stored in a cold or frozen state. It will be understood that the preparation is produced under aseptic conditions.
  • the invention also relates to a method of preparing a nutrient solution, which comprises the steps of trans ⁇ ferring a solution of amino acids, fat emulsion and/or energy substrate to the glutamine preparation, said solution being enclosed in a container which is placed under a pressure that is higher than the pressure over the preparation.
  • An alternative method of preparing this nutrient solution is characterized by enclosing a solution of amino acids, fat emulsion and/or energy substrate in a container which is placed under a pres ⁇ sure that is lower than atmospheric pressure, and by reconstituting the glutamine preparation and transfer ⁇ ring said reconstituted preparation to said solution under the influence of a pressure which is greater than the pressure over the solution.
  • a conceivable alternative to the aforedescribed embodi ⁇ ments of the preparation is to pour the sterile-filtered solution containing free glutamine and at least one glutamine derivative/glutamine precursor into an appro ⁇ priate container, freezing the container and its con ⁇ tents, delivering said container to the destination and storing the container in a frozen state (at about -20°C) until the time of its use.
  • the solution can be stored in cold conditions (+2°C to +8°C) over a shorter period of time.
  • the final parenteral nutrient solution can be prepared in accordance with any one of a number of different methods, the method chosen depending on the chosen form of the inventive preparation and on which other compo ⁇ nents shall be present in the final nutrient solution.
  • a number of examples of different methods of producing the inventive preparation are described below. These examples take their starting point from an inventive preparation of a freeze-dried powder, which is the alternative of most interest from a commercial and handling aspect.
  • the third alternative method of preparing the preparation is chosen (solution/deep- frozen solution of free glutamine and at least one glutamine derivative), it is, of course, possible to use the solution directly, subsequent to bringing the solu ⁇ tion to a suitable temperature.
  • a main component In the case of partial nutrient therapy, it is often desired to administer a main component, this component normally being contained in a single package or dosage unit.
  • a main component for example, it is possible to administer a glu ⁇ cose solution, or to administer an amino acid solution in order to improve the patient's nitrogen balance.
  • glutamine the freeze- dried preparation can be dissolved in a part of the aforesaid solution.
  • the transfer of liquid between the containers can be effected, by creating a partial vacuum in the receiving container (see the following) .
  • a con ⁇ centrated glucose solution alternatively an amino acid solution or a fat emulsion
  • this solution can be transferred, in turn, to the glucose/ amino acid/solution or to the fat emulsion present in an incompletely filled container under vacuum.
  • these components can be supplied by simultaneous or consecutive infusion from different bottles or other container types.
  • the present invention involves the aforediscussed prob ⁇ lems concerning large volumes, high costs, metabolic imbalances and the necessity of carrying out co prehen- sive analytical and biological processes, and provides a nutrient solution which fulfils all requirements with respect to variation, sterility, stability and nutri ⁇ tional balance.
  • the solution contains both free, natural L- gluta ine and one or more glutamine-containing peptides and/or metabolic precursors to glutamine, it is possible to obtain sufficiently high quantities of glutamine without supplying unfavourable quantities of either peptide or other amino acids in the peptide, for example glycine and alanine, and without the volumes supplied or the resulting costs being unrealistic.
  • the preparation may also contain other nutrient components, such as amino acids, carbohydrates, vita- mins, etc.
  • the costs represented by the freeze-drying process can be carried by/shared among the various components.
  • Vamin ® 14 EF, Vamin ® 18 EF, and Vamin ® 9 Glucose are concentrated amino acid solutions.
  • Intralipid ® is a 20% fat emulsion for intravenous nutrient supply.
  • Addamel ® is an additive solution with electrolytes and trace elements.
  • - Addiphos ® is an additive solution with phosphate.
  • Soluvit ® is a mixture of water-soluble vitamins.
  • Vitalipid ® is an additive solution in emulsion form, containing fat-soluble vitamins.
  • KABI Bag ® is a 3-litre mixing bag by means of which a complete nutrient mixture can be administered to the patient.
  • a solution was prepared by dissolving 7.5 g of L-gluta ⁇ mine, 14.0 g of glycyl-L-glutamine, and 5.0 g of alanyl- L-glutamine in a total volume of 250 ml of distilled, pyrogen-free water.
  • the solution was sterile-filtered and poured into a 1- litre bottle under aseptic conditions. The solution was then frozen and freeze-dried under aseptic conditions, whereafter the bottle was sealed in the freeze drier prior to interrupting the vacuum.
  • the freeze-dried solution Prior to use, the freeze-dried solution was reconstitu ⁇ ted, by adding 500 ml of Vamin 18 EF ® . This transfer was effected by placing the freeze-dried glutamine under partial vacuum and drawing the Vamin to the glutamine by suction with the aid of a transfer device constructed herefor.
  • a solution was prepared by dissolving 7 g of L-glutamine 10.0 g of glycyl-L-glutamine and 10.0 g of alpha- keto- glutarate (the monosodium salt) in a total volume of 250 ml of distilled, pyrogen-free water.
  • the solution was sterile filtered and poured into a 1- litre bottle under aseptic conditions. The solution was then frozen and freeze-dried under aseptic conditions. The bottle was sealed in the freeze-drier, prior to interrupting the vacuum.
  • the freeze-dried solution Prior to use, the freeze-dried solution was reconstitu- ted by adding 500 ml of Vamin 18 EF ® .
  • the transfer of Vamin to the freeze-dried solution was effected by placing the glutamine under a partial vacuum and drawing the Vamine to the glutamine by suction with the aid of a transfer device constructed herefor.
  • a solution was prepared by mixing 4 g of L-glutamine, 10.0 g of glycyl-L-glutamine, 8.0 g of alanyl-L-gluta- mine and 8.0 g of alpha-keto-glutarate (as the ornithine salt) in a total volume of 250 ml of distilled, pyrogen- free water.
  • the solution was sterile-filtered and poured into a 1- litre bottle under aseptic conditions.
  • the solution was then frozen and freeze-dried under aseptic conditions.
  • the bottle was sealed in the freeze drier, prior to interrupting the vacuum.
  • the freeze-dried solution was reconstituted by adding 500 ml of a 20%-glucose solution.
  • the transfer of the glucose solution to the freeze-dried solution was ef ⁇ fected by placing the glutamine under a partial vacuum and drawing the solution to the glutamine by suction with the aid of a transfer device constructed herefor.
  • a solution was prepared by dissolving 6 g of L-gluta ⁇ mine, 10 g of glycyl-L-glutamine and 10 g of alpha-keto- glutarate (as the arginine salt) in a total volume of
  • a solution was prepared by dissolving 9.0 g of L-gluta ⁇ mine, 14.0 g of glycyl-L-glutamine, 9.0 g of alanyl-L- gluta ine and 50 g of glucose in a total volume of 250 ml of distilled, pyrogen-free water.
  • the solution was sterile-filtered and poured into a 1- litre bottle under aseptic conditions.
  • the solution was frozen and freeze-dried under aseptic conditions.
  • the bottle was sealed in the freeze-drier, prior to interrupting the vacuum.
  • the freeze-dried solution Prior to use, the freeze-dried solution was reconstitu- ted by adding 500 ml of Vamin 14 EF ® .
  • the transfer of Vamin to the freeze-dried solution was effected by placing the glutamine under a partial vacuum and drawing the Vamine to the glutamine by suction with the aid of a transfer device constructed herefor.
  • An ampull contain- ing Addamel N ® (10 ml) was added to the solution ob ⁇ tained.
  • This example provided a complete amino acid solution, containing glutamine, which covers low requirements of amino acids, glucose and trace substances.
  • a solution was prepared by dissolving 7.0 g of L-gluta ⁇ mine, 18.0 g of glycyl-L-glutamine, 15.0 g of alanyl-L- glutamine and 100 g of glucose in a total volume of 300 ml distilled, pyrogen-free water.
  • the solution was sterile-filtered and poured into a 1- litre bottle under aseptic conditions.
  • the solution was frozen and freeze-dried under aseptic conditions.
  • the bottle was sealed in the freeze drier, prior to inter ⁇ rupting the vacuum.
  • the freeze-dried solution Prior to use, the freeze-dried solution was reconstitu ⁇ ted by adding at least 500 ml of Vamin 9 Glucose ® taken from a 1000 ml-bottle.
  • the transfer of Vamin to the freeze-dried solution was effected by placing the gluta ⁇ mine under a partial vacuum and drawing the Vamine to the glutamine by suction with the aid of a transfer device constructed herefor.
  • the reconstituted solution and any residue of the Vamin 9 solution was transferred to a 3-litre mixing bag of the KABI Bag type.
  • Intralipid ® 20% 500 ml Intralipid ® 20% were then added to the mixing bag.
  • a solution was prepared by dissolving 2.7 g of L-gluta ⁇ mine, 20.0 g of glycyl-L-glutamine and 11.8 g of alanyl- L-glutamine in 100 ml of sterile, pyrogen-free water.
  • the solution was sterile-filtered and poured aseptically into a sterile 100 ml glass bottle.
  • the solution was cooled and stored at a temperature of +2°C to +8°C up to its time of use, within 7 days.
  • a solution was prepared by dissolving 2.7 g of L-gluta ⁇ mine, 20.0 g of glycyl-L-glutamine and 11.8 g of alanyl- L-glutamine in 100 ml of sterile, pyrogen-free water.
  • the solution was sterile-filtered and poured aseptically into a sterile 100 ml plastic container.
  • the solution was frozen and stored at a temperature of about -18°C. Prior to use, the solution was thawed at a temperature of at most +40 ° C , prior to being administered as an infusion, or prior to being included in a mixture of nutrient solutions.
  • a powder mixture was introduced into a 3-litre plastic container of the KABI Bag ® type.
  • the mixture contained 40 g of L-glutamine and 10 g of alpha-keto-glutarate.
  • the plastic container was then sealed and radiation- sterilized with a radiation dosage of 25 kiloGray.
  • nutrient solutions Prior to use, nutrient solutions were introduced to the container in accordance with the following program, such as to obtain a fully balanced nutrient solution for patient administration. 750 ml of Intralipid ® 20%, 1000 ml of Vamin 14 EF, 1000 ml of glucose solution (30%) and appropriate trace elements, electrolytes, water-soluble and fat-soluble vitamins in the form of the preparations Addamel, Addiphos, Soluvit and Vitalipid, were added introduced into the mixing bag. (Were added to the amino acid solution or the fat emulsion prior to mixing in the KABI Bag).
  • a powder mixture was introduced into a 200 ml plastic container which ' included suitable ports for aseptic solution supply and solution tapping purposes.
  • the mixture contained 5 g of L-glutamine and 20 g of glycyl- L-glutamine.
  • the plastic container was sealed and then radiation sterilized with a radiation dosage of 25 kiloGray.
  • This example provides a concentrated additive solution of glutamine.
  • a solution was prepared by dissolving 7.0 g of L-gluta ⁇ mine, 20.0 g of glycyl-L-glutamine, 12.8 g of alanyl-L- glutamine, 1.05 g of L-isoleucine , 1.50 g of L-leucine, 1.70 g of L-lysine, 1.05 g of L-methionine, 0.10 g of L- cysteine, 1.50 g of L-phenyl alanine, 0.04 g of L- thryosine, 1.05 g of L-threonine, 0.35 g of L-trypto- phan, 1.38 g of L-valine, 3.00 g of L-alanine, 2.10 g of L-arginine, 0.63 g of L-asparaginic acid, 1.05 g of L- gluta ic acid, 1.30 g of L-histidine, 1.30 g of L-proline, 0.85 g of L-ser
  • the solution was sterile-filtered and poured into a 1- litre bottle under aseptic conditions.
  • the solution was frozen and freeze-dried under aseptic conditions.
  • the bottle was sealed in the freeze drier prior to interrupting the vacuum.
  • the freeze-dried solution was reconstituted by adding 500 ml of a 10%-glucose solution.
  • the transfer of the glucose solution to the ' freeze-dried solution was effected by placing the glutamine under a partial vacuum and drawing the solution to the glutamine by suction with the aid of a transfer device constructed herefor.

Abstract

The invention relates to a composition for oral or parenteral use, characterized in that the composition contains free L-glutamine and also at least one derivative of L-glutamine and optionally at least one precursor to L-glutamine, the composition being prepared aseptically and freeze-dried in powder form and radiation-sterilized, or in the form of a solution which is stored at low temperature, preferably in deep-frozen form. The derivative preferably consists of peptides, such as glycyl-L-glutamine and/or L-alanyl-L-glutamine, and the precursor may consist of alpha-keto-glutaric acid or the salt/derivative thereof. The derivative may also consist of N-acetyl-L-glutamine. The composition may also contain other nutrient components, or technical auxiliary substances, such as carbohydrates, sugar alcohols, vitamins and/or amino acids, preferably in freeze-dried form. The invention also relates to the production of the composition and to a method of preparing a nutrient solution.

Description

NUTRIENT SUPPLY
The present invention relates to a preparation which makes possible the parenteral or oral administration of a balanced nutrient solution containing a high concen¬ tration of glutamine and gluta ine derivative or gluta- mine precursors.
More specifically, but not exclusively, the invention relates to a preparation which contains L-glutamine and also at least one glutamine derivative, preferably glycyl-L-glutamine and/or L-alanyl-L-glutamine or a precursor of L-glutamine, preferably alpha-keto-glutaric acid and salts/derivatives thereof. N-acetyl-L-gluta¬ mine can also be used.
The invention also relates to a nutrient solution and to a method of preparing the same, said solution optionally containing such nutrients as amino acids, fats, particu¬ larly emulsified fats, energy substrates, such as glu¬ cose, sugar alcohols and keto-aσids, electrolytes, vitamins and trace elements.
Background
Intravenous nutrient therapy has become progressively more complete and better balanced as the significance of new substances, or the significance of substances which have earlier been overlooked, has become more apparent.
Observations made in recent years have shown that gluta¬ mine is highly significant when used as a component of nutrient support compositions. In the metabolic circu- lation of nitrogen, glutamine is the most significant transporter by means of which nitrogen is transported from muscle to intestines and liver. According to certain theories, glutamine has a stimulating effect on the synthesis of proteins in muscle tissue. The store of free glutamine in skeletal muscle diminishes drasti- cally in patients who have suffered serious trauma, surgical operations, sepsis, etc. (Vinnars E. , Berg- strδm, and First, P. : Influence of the Postoperative State on the Intracellular Free Amino Acids in Human Muscle Tissue; Annals of Surgery 182:665-671 (1975) and Askanazi, J. , et al: Muscle and Plasma Amino Acids Follow Injury. Influence of Intercurrent Infection. Ann Surg. 192:78-85 (1980.) .
Glutamine also constitutes an essential energy source for the intestinal mucus membrane (Windmueller, H.G., Spaeth, A.E.: Identification of Ketone Bodies and Glutamine as the Major Respiratory Fuels in Vivo for Postabsorptive Rat Small Intestine, J. Biol. Chem. 253:69-76 (1978). Total intravenous nutrition results in some degree of atrophication or wasting of the intes¬ tine mucus membrane. Animal experimentation has shown that glutamine is able to counteract this negative effect, when administered intravenously. The atrophica- tion of intestine mucus membrane observed in conjunction with intravenous nutrition, and also in conjunction with serious trauma, can contribute to the passage of bac¬ teria from the wall of the intestine into the blood, which can have a decisive influence on the ability of the patient to survive. The administration of glutamine to animals suffering from experimentally induced bowel damage has been found to result in a lower mortality rate (Hwang, T.L. , et al: Preservation of Small Bowel Mucosa Using Glutamine-Enriched Parenteral Nutrition. Surg. Forum 37:56-58 (1986). An optimal treatment with the intention of maintaining normal bowel wall function would therefore seem to require the administration of considerable quantities of glutamine, for example in the case of serious trauma, sepsis and burns, for patients treated with cytostatic or radioactive radiation, and also in the case of in¬ flammatory diseases, such as morbus Chron or ulcerative colitis.
A nutrient solution which contains glutamine together with other nutritious substances is highly desirable. The problem with such solutions, however, is that solu¬ tions which contain glutamine cannot be sterilized by autoclaving, since free glutamine in solution is not heat resistant. When a solution which contains gluta¬ mine is heated or stored for long periods of time at room temperature, the glutamine will decompose to ammo¬ nia and pyroglutamic acid. Such substances are unac¬ ceptable in nutrient solutions intended for intravenous administration. Consequently, present-day commercially available parenteral nutrient amino acid solutions con¬ tain no glutamine.
Alpha-keto-glutarate (AKG) is active in various trans- amination reactions and thereby adopts a central roll in the amino acid metabolism. It has long been known that glutamine can be formed from AKG via glutamic acid. It has also been found that when administered intra¬ venously, AKG is able to counteract the depletion of the free content of glutamine intracellular in muscle after operative trauma (Wernerman, et al, The Lancet 335, No. 8691, 701-703, 1990). This indicates that AKG could be used as a glutamine precursor in an intravenous nutrient supply or support. Wilmore (WO 87/01587) discloses the use of glutamine in quantities of up to 0.2-3 g/kg of body weight and day in conjunction with trauma.
Veech (WO 87/03806) utilizes glutamine, optionally in mixture with AKG in small quantities, to influence the redox system.
Vinnars (EP 0 318 446) discloses the composition of a posttraumatic solution treatment. Although based on a conventional amino acid mixture, this composition is characterized in that it also includes 5-30 g glutamine and/or 5-25 g AKG per litre, and optional L-asparagine and acetoacetate.
It has been found that peptide-bound glutamine, e.g. glycyl-L-glutamine and also L-alanyl-L-glutamine are acceptably stable when subjected to heat treatment in solution; it has also been found that these substances are biologically active as a glutamine source. This also applies to N-acetyl-L-glutamine. ' Fϋrst, et al (DE 3206 784) discloses an amino acid solution which is characterized in that it contains glutamine in the form of water-soluble dipeptides or tripeptides.
Adibi (BE-887941) discloses an aqueous solution which contains at least two dipeptides or tripeptides having a single glycine molecule as the N-terminal amino acid.
Magnusson, et al (SE 8703567-1) discloses an amino acid solution which is characterized in that it contains 2-30 g of N-acetyl-L-glutamine per litre of solution. Problems
Nutrient solutions for parenteral administration (Large Volume Parenterals) are normally sterilized at about 121°C for 15 minutes, in accordance with standardized techniques. When the solutions contain components that are able to react with one another or which become unstable when subjected to heat, it is not, however, possible to follow the standardized procedures. Thus, none of the commercially available amino acid solutions contains glutamine.
Our earlier patent application, SE 8902544-9, discloses a method of solving the problem of the instability of glutamine, this solution involving the sterilization of powdered glutamine by ionizing radiation prior to mixing the glutamine with the remaining components in the nutrient solution.
It is also conceivable to freeze-dry a sterile filtered glutamine solution and to dissolve the freeze-dried powder aseptically in conjunction with its use. How¬ ever, because glutamine is not readily dissolvable, the dissolution of glutamine requires the use of large volumes of liquid, which renders the freeze-drying process considerably expensive. Since it is necessary to dissolve the freeze-dried glutamine in corresponding volumes of liquid, this method would also necessitate administering large quantities of liquid to the patient , which is not possible or feasible in many instances.
For example, the administration of 60 grams of L-gluta¬ mine would require a liquid volume in excess of 2 litres.
A third possibility is to supply the glutamine in the form of a precursor which can be converted at least partially to glutamine in the body.
It is impossible, however, to administer large quanti¬ ties of AKG, in view of the resultant pH-values (very low), among other things. Neither is it possible to administer large quantities of AKG in the form of sodium or calcium salt, in view of the non-physiological load represented by these mineral substances. Corresponding¬ ly, the administration of large quantities of the neu- tral ornithine salt of the alpha-keto-glutarate would subject the body to an unreasonable quantity of ornithine.
A fourth possibility is one of administering glutamine in the form of a derivative, preferably in the form of a dipeptide. However, when it is necessary to administer glutamine in large quantities, the other amino acid in the dipeptide, preferably glycine or alanine, will also be present in large quantities. (A daily dosage of 60 g glutamine corresponds, e.g., to 37 grams of alanine, alternatively 31 grams of glycine, depending on whether the supply is effected in the form of the alanyl-peptide or the glycyl-peptide). From the physiological aspect, this implies unfavourable quantities of glycine or alanine. When supplying the glutamine peptide to a commercial amino acid solution, the peptide-bound ala¬ nine or the peptide-bound glycine is also added to corresponding free amino acid in the solution, and the patient is thereby liable to obtain a negative imbalance in the amino acid conversion.
Furthermore, a supply of 80-90 g of a dipeptide would be likely to exceed the ability of the organism to cleave (hydrolyze) the peptide in order to release l-glutamine. This would result in a drastic increase in plasma levels of the peptide, pronounced secretion of the unconsumed peptide in the urine and therewith poor use of the peptide administered.
Furthermore, when in solution the dipeptides in question are, in many cases, not completely stable during the sterilizing process or when stored for long periods of time at room temperature. Consequently, the dipeptide solution must be subjected to comprehensive analytical and biological processes in order to ensure the quality of the peptide solutions from a technical and toxicolog- ical aspect.
Furthermore, the price per unit of glutamine based on a glutamine peptide is about 10-20 times higher than the price of a corresponding quantity of pure L-glutamine.
The proposed invention enables large quantities of glutamine to be administered without interference from the aforediscussed problems concerning technical insta- bility, large volumes when dissolving and administering glutamine, and, particularly with respect to peptide supply, high costs, metabolic imbalances and physiologi¬ cal overloads.
Detailed description of the invention
The invention relates to a preparation for oral or parenteral use, characterized in that the preparation includes free L-glutamine and also at least one L- glutamine derivative and optionally at least one L- glutamine precursor, said preparation being prepared aseptically and freeze-dried; in that the preparation is in powder form and is radiation sterilized, or is in the form of a solution which is stored at low temperature, preferably in a frozen state. By low temperature is meant a temperature lower than room temperature, and preferably a temperature within the range of 2-8βC.
The derivative preferably consists of peptides, such as glycyl-L-glutamine and/or L-alanyl-L-glutamine, and the precursor may consist of alpha-keto-glutaric acid or the salt/derivative thereof. The derivative may also con¬ sist of N-acetyl-L-glutamine.
In addition to containing L-glutamine and at least one derivative of L-glutamine and/or a precursor to L-gluta¬ mine, the preparation may also contain other nutrient components, alternatively technical auxiliary sub¬ stances, such as carbohydrates, sugar alcohols, vitamins and/or amino acids, preferably in freeze-dried form.
The present invention also relates to a nutrient solu¬ tion which contains the aforedescribed preparation and further amino acids, fat emulsion, energy substrate, such as glucose, sugar alcohols and keto-acids, vita- mins, electrolytes and/or trace elements.
According to one method, the claimed preparation is produced by dissolving the preparation components, sterile filtering the solution and thereafter freeze- drying the sterile solution.
According to an alternative method, the components are mixed together in powder form and the resultant mixture is then sterilized by radiation.
According to another alternative, the preparation compo¬ nents are mixed in solution and the solution is sterile filtered and stored in a cold or frozen state. It will be understood that the preparation is produced under aseptic conditions. The invention also relates to a method of preparing a nutrient solution, which comprises the steps of trans¬ ferring a solution of amino acids, fat emulsion and/or energy substrate to the glutamine preparation, said solution being enclosed in a container which is placed under a pressure that is higher than the pressure over the preparation. An alternative method of preparing this nutrient solution is characterized by enclosing a solution of amino acids, fat emulsion and/or energy substrate in a container which is placed under a pres¬ sure that is lower than atmospheric pressure, and by reconstituting the glutamine preparation and transfer¬ ring said reconstituted preparation to said solution under the influence of a pressure which is greater than the pressure over the solution.
A conceivable alternative to the aforedescribed embodi¬ ments of the preparation is to pour the sterile-filtered solution containing free glutamine and at least one glutamine derivative/glutamine precursor into an appro¬ priate container, freezing the container and its con¬ tents, delivering said container to the destination and storing the container in a frozen state (at about -20°C) until the time of its use. Alternatively, the solution can be stored in cold conditions (+2°C to +8°C) over a shorter period of time.
The final parenteral nutrient solution can be prepared in accordance with any one of a number of different methods, the method chosen depending on the chosen form of the inventive preparation and on which other compo¬ nents shall be present in the final nutrient solution. A number of examples of different methods of producing the inventive preparation are described below. These examples take their starting point from an inventive preparation of a freeze-dried powder, which is the alternative of most interest from a commercial and handling aspect. When the third alternative method of preparing the preparation is chosen (solution/deep- frozen solution of free glutamine and at least one glutamine derivative), it is, of course, possible to use the solution directly, subsequent to bringing the solu¬ tion to a suitable temperature.
In the case of partial nutrient therapy, it is often desired to administer a main component, this component normally being contained in a single package or dosage unit. For example, it is possible to administer a glu¬ cose solution, or to administer an amino acid solution in order to improve the patient's nitrogen balance. When wishing to also administer glutamine, the freeze- dried preparation can be dissolved in a part of the aforesaid solution. The transfer of liquid between the containers can be effected, by creating a partial vacuum in the receiving container (see the following) .
An advantage can be gained in this case, when signifi¬ cant quantities of nutrient components are already present in the freeze-dried preparation.
It is often desired to administer the patient with a more complete nutrient mixture that contains glutamine. In this case, the technique of transferring solution from one container to another with the aid of a partial vacuum can be beneficially applied.
In this case, there is preferably transferred to the inventive preparation of freeze-dried glutamine a con¬ centrated glucose solution, alternatively an amino acid solution or a fat emulsion, with the inventive prepara- tion placed under a partial vacuum. Subsequent to dissolution of the freeze-dried substances and equalization of the pressure in the container, this solution can be transferred, in turn, to the glucose/ amino acid/solution or to the fat emulsion present in an incompletely filled container under vacuum. In this way, there is obtained a nutrient solution which con¬ tains several significant nutrient components that can be administered to the patient from one single package, which affords important advantages in practice.
When it is desired to administer to a patient a solution that contains all the necessary nutrient components, these components can be supplied by simultaneous or consecutive infusion from different bottles or other container types.
It is often preferred to administer a complete mixture of nutrient components from one single container (nor¬ mally a 3-litre plastic container). However, it is necessary to prepare such a mixture regularly from individual nutrient solutions at the time of use, or is obtained from the supplier in the form of a prepared mixture. An inventive glutamine preparation is also used in these cases to produce a glutamine-containing nutrient solution, which is then transferred to the mixing container.
The present invention involves the aforediscussed prob¬ lems concerning large volumes, high costs, metabolic imbalances and the necessity of carrying out co prehen- sive analytical and biological processes, and provides a nutrient solution which fulfils all requirements with respect to variation, sterility, stability and nutri¬ tional balance.
Because the solution contains both free, natural L- gluta ine and one or more glutamine-containing peptides and/or metabolic precursors to glutamine, it is possible to obtain sufficiently high quantities of glutamine without supplying unfavourable quantities of either peptide or other amino acids in the peptide, for example glycine and alanine, and without the volumes supplied or the resulting costs being unrealistic.
Because the preparation may also contain other nutrient components, such as amino acids, carbohydrates, vita- mins, etc., the costs represented by the freeze-drying process can be carried by/shared among the various components. When the solution is prepared under the aforedescribed .conditions and stored in a freeze-dried state, all problems relating to instability when prepar- ing the preparation and during the storage thereof are avoided.
Completely new possibilities for complete nutrient therapy capable of being adapted to the needs of each individual patient are achieved by combining the freeze- dried material with different nutrient solutions accord¬ ing to the disclosures set forth in the following Examples 1-11.
Corresponding advantages are also achieved when the mixture of glutamine components is radiation sterilized or prepared aseptically and deep-freezed.
Examples
The following named products from KABI Nutrition AB, Stockholm, were used in the Examples.
" Vamin®14 EF, Vamin®18 EF, and Vamin®9 Glucose are concentrated amino acid solutions. Intralipid® is a 20% fat emulsion for intravenous nutrient supply.
Addamel® is an additive solution with electrolytes and trace elements. - Addiphos® is an additive solution with phosphate. Soluvit® is a mixture of water-soluble vitamins. Vitalipid® is an additive solution in emulsion form, containing fat-soluble vitamins. KABI Bag® is a 3-litre mixing bag by means of which a complete nutrient mixture can be administered to the patient.
Example 1
A solution was prepared by dissolving 7.5 g of L-gluta¬ mine, 14.0 g of glycyl-L-glutamine, and 5.0 g of alanyl- L-glutamine in a total volume of 250 ml of distilled, pyrogen-free water.
The solution was sterile-filtered and poured into a 1- litre bottle under aseptic conditions. The solution was then frozen and freeze-dried under aseptic conditions, whereafter the bottle was sealed in the freeze drier prior to interrupting the vacuum.
Prior to use, the freeze-dried solution was reconstitu¬ ted, by adding 500 ml of Vamin 18 EF®. This transfer was effected by placing the freeze-dried glutamine under partial vacuum and drawing the Vamin to the glutamine by suction with the aid of a transfer device constructed herefor.
This example provides a complete amino acid solution containing glutamine, which satisfies basal amino acid requirements. Example 2
A solution was prepared by dissolving 7 g of L-glutamine 10.0 g of glycyl-L-glutamine and 10.0 g of alpha- keto- glutarate (the monosodium salt) in a total volume of 250 ml of distilled, pyrogen-free water.
The solution was sterile filtered and poured into a 1- litre bottle under aseptic conditions. The solution was then frozen and freeze-dried under aseptic conditions. The bottle was sealed in the freeze-drier, prior to interrupting the vacuum.
Prior to use, the freeze-dried solution was reconstitu- ted by adding 500 ml of Vamin 18 EF®. The transfer of Vamin to the freeze-dried solution was effected by placing the glutamine under a partial vacuum and drawing the Vamine to the glutamine by suction with the aid of a transfer device constructed herefor.
Example 3
A solution was prepared by mixing 4 g of L-glutamine, 10.0 g of glycyl-L-glutamine, 8.0 g of alanyl-L-gluta- mine and 8.0 g of alpha-keto-glutarate (as the ornithine salt) in a total volume of 250 ml of distilled, pyrogen- free water.
The solution was sterile-filtered and poured into a 1- litre bottle under aseptic conditions.
The solution was then frozen and freeze-dried under aseptic conditions. The bottle was sealed in the freeze drier, prior to interrupting the vacuum. Prior to use, the freeze-dried solution was reconstituted by adding 500 ml of a 20%-glucose solution. The transfer of the glucose solution to the freeze-dried solution was ef¬ fected by placing the glutamine under a partial vacuum and drawing the solution to the glutamine by suction with the aid of a transfer device constructed herefor.
Example 4
A solution was prepared by dissolving 6 g of L-gluta¬ mine, 10 g of glycyl-L-glutamine and 10 g of alpha-keto- glutarate (as the arginine salt) in a total volume of
300 ml of distilled, pyrogen-free water. The remainder of the preparation process was effected in accordance with Example 3.above.
Example 5
A solution was prepared by dissolving 9.0 g of L-gluta¬ mine, 14.0 g of glycyl-L-glutamine, 9.0 g of alanyl-L- gluta ine and 50 g of glucose in a total volume of 250 ml of distilled, pyrogen-free water.
The solution was sterile-filtered and poured into a 1- litre bottle under aseptic conditions.
The solution was frozen and freeze-dried under aseptic conditions. The bottle was sealed in the freeze-drier, prior to interrupting the vacuum.
Prior to use, the freeze-dried solution was reconstitu- ted by adding 500 ml of Vamin 14 EF®. The transfer of Vamin to the freeze-dried solution was effected by placing the glutamine under a partial vacuum and drawing the Vamine to the glutamine by suction with the aid of a transfer device constructed herefor. An ampull contain- ing Addamel N® (10 ml) was added to the solution ob¬ tained. This example provided a complete amino acid solution, containing glutamine, which covers low requirements of amino acids, glucose and trace substances.
Example 6
A solution was prepared by dissolving 7.0 g of L-gluta¬ mine, 18.0 g of glycyl-L-glutamine, 15.0 g of alanyl-L- glutamine and 100 g of glucose in a total volume of 300 ml distilled, pyrogen-free water.
The solution was sterile-filtered and poured into a 1- litre bottle under aseptic conditions. The solution was frozen and freeze-dried under aseptic conditions. The bottle was sealed in the freeze drier, prior to inter¬ rupting the vacuum.
Prior to use, the freeze-dried solution was reconstitu¬ ted by adding at least 500 ml of Vamin 9 Glucose® taken from a 1000 ml-bottle. The transfer of Vamin to the freeze-dried solution was effected by placing the gluta¬ mine under a partial vacuum and drawing the Vamine to the glutamine by suction with the aid of a transfer device constructed herefor. The reconstituted solution and any residue of the Vamin 9 solution was transferred to a 3-litre mixing bag of the KABI Bag type.
500 ml Intralipid® 20% were then added to the mixing bag. Appropriate trace elements, electrolytes, water- soluble and fat-soluble vitamins, in the form of prepa¬ rations Addamel, Addiphos, Soluvit and Vitalipid, were added to the amino acid solution or to the fat emulsion prior to mixing in the KABI Bag.
The procedure described in this example enables a com¬ plete nutrient solution containing glutamine to be obtained in a simple fashion.
Example 7
A solution was prepared by dissolving 2.7 g of L-gluta¬ mine, 20.0 g of glycyl-L-glutamine and 11.8 g of alanyl- L-glutamine in 100 ml of sterile, pyrogen-free water. The solution was sterile-filtered and poured aseptically into a sterile 100 ml glass bottle. The solution was cooled and stored at a temperature of +2°C to +8°C up to its time of use, within 7 days.
Example 8
A solution was prepared by dissolving 2.7 g of L-gluta¬ mine, 20.0 g of glycyl-L-glutamine and 11.8 g of alanyl- L-glutamine in 100 ml of sterile, pyrogen-free water. The solution was sterile-filtered and poured aseptically into a sterile 100 ml plastic container. The solution was frozen and stored at a temperature of about -18°C. Prior to use, the solution was thawed at a temperature of at most +40 ° C , prior to being administered as an infusion, or prior to being included in a mixture of nutrient solutions.
Example 9
A powder mixture was introduced into a 3-litre plastic container of the KABI Bag® type. The mixture contained 40 g of L-glutamine and 10 g of alpha-keto-glutarate. The plastic container was then sealed and radiation- sterilized with a radiation dosage of 25 kiloGray.
Prior to use, nutrient solutions were introduced to the container in accordance with the following program, such as to obtain a fully balanced nutrient solution for patient administration. 750 ml of Intralipid® 20%, 1000 ml of Vamin 14 EF, 1000 ml of glucose solution (30%) and appropriate trace elements, electrolytes, water-soluble and fat-soluble vitamins in the form of the preparations Addamel, Addiphos, Soluvit and Vitalipid, were added introduced into the mixing bag. (Were added to the amino acid solution or the fat emulsion prior to mixing in the KABI Bag).
Example 10
A powder mixture was introduced into a 200 ml plastic container which' included suitable ports for aseptic solution supply and solution tapping purposes. The mixture contained 5 g of L-glutamine and 20 g of glycyl- L-glutamine. The plastic container was sealed and then radiation sterilized with a radiation dosage of 25 kiloGray.
Prior to use, 200 ml of sterile water were introduced into the container.
This example provides a concentrated additive solution of glutamine.
Example 11
A solution was prepared by dissolving 7.0 g of L-gluta¬ mine, 20.0 g of glycyl-L-glutamine, 12.8 g of alanyl-L- glutamine, 1.05 g of L-isoleucine , 1.50 g of L-leucine, 1.70 g of L-lysine, 1.05 g of L-methionine, 0.10 g of L- cysteine, 1.50 g of L-phenyl alanine, 0.04 g of L- thryosine, 1.05 g of L-threonine, 0.35 g of L-trypto- phan, 1.38 g of L-valine, 3.00 g of L-alanine, 2.10 g of L-arginine, 0.63 g of L-asparaginic acid, 1.05 g of L- gluta ic acid, 1.30 g of L-histidine, 1.30 g of L-proline, 0.85 g of L-serine, 1.50 g of glycine, and 50 g of glucose in a total volume of 350 ml of distilled, pyrogen-free water.
The solution was sterile-filtered and poured into a 1- litre bottle under aseptic conditions.
The solution was frozen and freeze-dried under aseptic conditions. The bottle was sealed in the freeze drier prior to interrupting the vacuum. Prior to use, the freeze-dried solution was reconstituted by adding 500 ml of a 10%-glucose solution. The transfer of the glucose solution to the' freeze-dried solution was effected by placing the glutamine under a partial vacuum and drawing the solution to the glutamine by suction with the aid of a transfer device constructed herefor.

Claims

1. A composition for oral or parenteral use, c h a r a c t e r i z e d in that the composition contains free L-glutamine and also at least one deri- vate of L-glutamine and optionally at least one precur¬ sor to L-glutamine.
2. A composition according to claim 1, c h a r a c- t e r i z e d in that said composition is prepared aseptically and freeze-dried.
3. A composition according to claim 1 c h a r a c¬ t e r i z e d in that said composition is in powder form and is radiation sterilized.
4. A composition according to claim 1, c h a r a c¬ e r i z e d in that said composition is in the form of a solution which is stored at low temperature, pref- erably in a deep-frozen form.
5. A composition according to any one of Claims 1-4, c h a r a c t e r i z e d in that the derivative con¬ sists of peptides, preferably glycyl-L-glutamine and/or L-alanyl-L-glutamine.
6. A composition according to any one of claims 1-4, c h a r a c t e r i z e d in that the derivative is N-acetyl-L-glutamine .
1. A composition according to any one of Claims 1-4, c h a r a c t e r i z e d in that the precursor is alpha-keto-glutaric acid or a salt/derivative thereof.
8. A composition according to any one of the preceding Claims, c h a r a c t e r i z e d in that the composi- tion contains other nutrient components, such as carbo¬ hydrates, sugar alcohols, vitamins and/or amino acids, in addition to L-glutamine and at least one derivative of L-glutamine and/or at least one precursor to L-glutamine.
9. A composition according to Claim 8, c h a r a c ¬ t e r i z e d in that it is freeze-dried.
10. A nutrient solution, c h a r a c t e r i z e d in that the solution contains the composition according to any one of the preceding Claims, together with addi¬ tional amino acids, fat emulsions, energy substrates, such as glucose, sugar alcohols and keto-acids, vita- ins, electrolytes and/or trace elements.
11. A method of producing a composition according to Claim 2 or Claim 8, c h a r a c t e r i z e d by dissolving the components, sterile-filtering the solu- tion and thereafter freeze-drying the sterile solution.
11. A method of producing a composition according to Claim 3 or Claim 8, c h a r a c t e r i z e d by mixing the components in powder form and radiation- sterilizing the resultant mixture.
12. A method of producing a composition according to Claim 4 or Claim 8, c h a r a c t e r i z e d by mixing the components in solution, sterile-filtering the solution and storing the solution under cold conditions or deep-freezing the solution.
14. A method of producing a nutrient solution according to Claim 10, c h a r a c t e r i z e d by transferring a solution of amino acids, fat emulsion and/or energy substrate to the composition according to any one of Claims 1-4 or according to Claim 8, said solution being enclosed in a container which is placed under a pressure that is higher than the pressure maintained over the composition.
15. A method of producing a nutrient solution according to Claim 10, c h a r a c t e r i z e d by enclosing a solution of amino acids, fat emulsion and/or energy substrate in a container which is placed under a pres- sure that is lower than atmospheric pressure, and by transferring the composition according to any one of Claims 1-4 or according to Claim 8, optionally in dis¬ solved form, to said solution under the influence of a pressure which is higher than the pressure maintained over the solution.
PCT/SE1991/000810 1990-12-03 1991-11-28 Nutrient supply WO1992009277A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9003844A SE9003844L (en) 1990-12-03 1990-12-03 NAERINGSTILLSATS
SE9003844-9 1990-12-03

Publications (1)

Publication Number Publication Date
WO1992009277A1 true WO1992009277A1 (en) 1992-06-11

Family

ID=20381081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1991/000810 WO1992009277A1 (en) 1990-12-03 1991-11-28 Nutrient supply

Country Status (3)

Country Link
AU (1) AU8931391A (en)
SE (1) SE9003844L (en)
WO (1) WO1992009277A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540462A1 (en) * 1991-10-10 1993-05-05 Sandoz Nutrition Ltd. L-Glutamine or a peptide rich in L-glutamine for the manufacture of an oral formulation for the treatment of a fall in blood L-glutamine levels
EP0634168A1 (en) * 1993-01-29 1995-01-18 Kyowa Hakko Kogyo Co., Ltd. Nutritive composition
WO1995011019A1 (en) * 1993-10-22 1995-04-27 Research Corporation Technologies, Inc. Glutamine-containing ingestible composition
WO1995012991A1 (en) * 1993-11-09 1995-05-18 Gramineer Ab New beverage
US5432160A (en) * 1993-01-29 1995-07-11 Kyowa Hakko Kohyo Co., Ltd. Nutrient composition
EP0665012A1 (en) * 1994-01-31 1995-08-02 Snow Brand Milk Products Co., Ltd. Antiallergy agent and nutritional composition containing glutamine and process for the production thereof
EP0666739A1 (en) * 1992-11-06 1995-08-16 Brigham And Women's Hospital An intravenous solution that diminishes body protein loss
GB2323030A (en) * 1997-03-12 1998-09-16 Essential Nutrition Ltd Dietary supplements for immunocompromised patients
US6649746B1 (en) 1999-05-07 2003-11-18 University Of Virginia Patent Foundation Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes
WO2004032653A1 (en) * 2002-10-08 2004-04-22 Abbott Laboratories Methods and compositions for providing glutamine
WO2007121807A1 (en) * 2006-04-20 2007-11-01 Fresenius Kabi Deutschland Gmbh Paediatric amino acid solution for parenteral nutrition
CN103936824A (en) * 2014-05-11 2014-07-23 孔凯明 Green preparation method of phthalylglycyl-L-glutamine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2529935A1 (en) * 1975-07-04 1977-01-13 Fresenius Chem Pharm Ind READY-TO-USE PACKED, BALANCED SYNTHETIC DIAETIC MIXTURE
WO1987001589A1 (en) * 1985-09-12 1987-03-26 Brigham And Women's Hospital Method of treating catabolic dysfunction
WO1987003806A1 (en) * 1985-12-18 1987-07-02 Veech Richard L Parenteral nutrition therapy with amino acids
WO1989003688A1 (en) * 1987-10-29 1989-05-05 Ab Erik Vinnars Amino acid composition for parenteral nutritional support and the use thereof
WO1991001135A1 (en) * 1989-07-17 1991-02-07 Kabivitrum Ab A nutritive composition and a method for its preparation
WO1991016067A1 (en) * 1990-04-23 1991-10-31 Research Corporation Technologies, Inc. Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2529935A1 (en) * 1975-07-04 1977-01-13 Fresenius Chem Pharm Ind READY-TO-USE PACKED, BALANCED SYNTHETIC DIAETIC MIXTURE
WO1987001589A1 (en) * 1985-09-12 1987-03-26 Brigham And Women's Hospital Method of treating catabolic dysfunction
WO1987003806A1 (en) * 1985-12-18 1987-07-02 Veech Richard L Parenteral nutrition therapy with amino acids
WO1989003688A1 (en) * 1987-10-29 1989-05-05 Ab Erik Vinnars Amino acid composition for parenteral nutritional support and the use thereof
WO1991001135A1 (en) * 1989-07-17 1991-02-07 Kabivitrum Ab A nutritive composition and a method for its preparation
WO1991016067A1 (en) * 1990-04-23 1991-10-31 Research Corporation Technologies, Inc. Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540462A1 (en) * 1991-10-10 1993-05-05 Sandoz Nutrition Ltd. L-Glutamine or a peptide rich in L-glutamine for the manufacture of an oral formulation for the treatment of a fall in blood L-glutamine levels
EP0666739A1 (en) * 1992-11-06 1995-08-16 Brigham And Women's Hospital An intravenous solution that diminishes body protein loss
EP0666739A4 (en) * 1992-11-06 1996-02-28 Brigham & Womens Hospital An intravenous solution that diminishes body protein loss.
EP0634168A1 (en) * 1993-01-29 1995-01-18 Kyowa Hakko Kogyo Co., Ltd. Nutritive composition
EP0634168A4 (en) * 1993-01-29 1995-02-08
US5432160A (en) * 1993-01-29 1995-07-11 Kyowa Hakko Kohyo Co., Ltd. Nutrient composition
WO1995011019A1 (en) * 1993-10-22 1995-04-27 Research Corporation Technologies, Inc. Glutamine-containing ingestible composition
WO1995012991A1 (en) * 1993-11-09 1995-05-18 Gramineer Ab New beverage
AU685882B2 (en) * 1993-11-09 1998-01-29 Gramineer Ab New beverage
US5817364A (en) * 1993-11-09 1998-10-06 Gramineer Ab Beverage containing alpha-ketoglutaric acid and method of making
EP0665012A1 (en) * 1994-01-31 1995-08-02 Snow Brand Milk Products Co., Ltd. Antiallergy agent and nutritional composition containing glutamine and process for the production thereof
GB2323030A (en) * 1997-03-12 1998-09-16 Essential Nutrition Ltd Dietary supplements for immunocompromised patients
US6649746B1 (en) 1999-05-07 2003-11-18 University Of Virginia Patent Foundation Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes
WO2004032653A1 (en) * 2002-10-08 2004-04-22 Abbott Laboratories Methods and compositions for providing glutamine
CN100382796C (en) * 2002-10-08 2008-04-23 艾博特公司 Methods and compositions for providing glutamine
WO2007121807A1 (en) * 2006-04-20 2007-11-01 Fresenius Kabi Deutschland Gmbh Paediatric amino acid solution for parenteral nutrition
EA015709B1 (en) * 2006-04-20 2011-10-31 Фрезениус Каби Дойчланд Гмбх Paediatric amino acid solution for parenteral nutrition and use thereof
CN103936824A (en) * 2014-05-11 2014-07-23 孔凯明 Green preparation method of phthalylglycyl-L-glutamine

Also Published As

Publication number Publication date
SE9003844L (en) 1992-06-04
SE9003844D0 (en) 1990-12-03
AU8931391A (en) 1992-06-25

Similar Documents

Publication Publication Date Title
Fürst New developments in glutamine delivery
EP0347890B1 (en) Amino acid nutrient compositions
Fürst et al. Glutamine‐containing dipeptides in parenteral nutrition
FI70794B (en) PROCEDURE FOR THE STABILIZATION OF THE PHARMACEUTICALS
US4670261A (en) Parenteral alimentation solution
JP2728134B2 (en) Amino acid composition for parenteral nutrition support
WO1992009277A1 (en) Nutrient supply
CA1341114C (en) Pharmaceutical formulations containing melphalan hydrochloride
Khan et al. The stability of L-glutamine in total parenteral nutrition solutions
KR970005837B1 (en) Process for preparing a solution with a high specific volume activity of a protein with a tissue plasminogen activator activity(t-pa), solution containing the protein with t-pa activity and fibinolytic composition containing this solution
CN102145009A (en) Octadeca compound amino acid injection and preparation method thereof
CN103110640B (en) Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection
Gouttebel et al. Influence of N‐acetylglutamine or glutamine infusion on plasma amino acid concentrations during the early phase of small‐bowel adaptation in the dog
Karner et al. Alanyl-glutamine infusions to patients with acute pancreatitis
EP0416108B1 (en) Nutritious composition
EP0355453A2 (en) Use of 3-hydroxybutyric acid as an energy source
Madan et al. Total parenteral nutrition
JPH06509362A (en) Alpha-ketol glutarate usage
JPH09110686A (en) Macrophage nitrogen monoxide-producing sthenic agent
JP4423682B2 (en) Preparation of freeze-dried glutamine for infusion
JPH07267855A (en) Glutamine producing agent
US20120329734A1 (en) Mixture and infusion or drink solution
JP3534535B2 (en) Glutamine-containing nutrient solution
Elia Glutamine in parenteral nutrition
JPH0940554A (en) Infusion containing glutamine and its production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA